EP1224169A2 - Indolinones substituees en position 5, leur production et leur utilisation comme medicament - Google Patents

Indolinones substituees en position 5, leur production et leur utilisation comme medicament

Info

Publication number
EP1224169A2
EP1224169A2 EP00966136A EP00966136A EP1224169A2 EP 1224169 A2 EP1224169 A2 EP 1224169A2 EP 00966136 A EP00966136 A EP 00966136A EP 00966136 A EP00966136 A EP 00966136A EP 1224169 A2 EP1224169 A2 EP 1224169A2
Authority
EP
European Patent Office
Prior art keywords
group
alkyl
phenyl
indolinone
phenylmethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00966136A
Other languages
German (de)
English (en)
Inventor
Gerald Jürgen Roth
Armin Heckel
Rainer Walter
Jacobus Meel Van
Norbert Redemann
Gisela Schnapp
Ulrike Tontsch-Grunt
Walter Spevak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1224169A2 publication Critical patent/EP1224169A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des indolinones substituées en position 5 de formule (I), dans laquelle R1 à R5 et X sont définis dans la revendication 1. Elle concerne également leurs isomères et leurs sels, notamment leurs sels physiologiquement tolérables. Ces composés présentent des propriétés pharmacologiques précieuses, notamment un effet inhibiteur sur différentes kinases et différents complexes cycline/CDK, sur les récepteurs tyrosine kinases ainsi que sur la prolifération de cellules tumorales. L'invention concerne également des médicaments contenant lesdits composés, leur utilisation et leur procédé de production.
EP00966136A 1999-10-13 2000-10-07 Indolinones substituees en position 5, leur production et leur utilisation comme medicament Withdrawn EP1224169A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19949209 1999-10-13
DE19949209A DE19949209A1 (de) 1999-10-13 1999-10-13 In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009847 WO2001027080A2 (fr) 1999-10-13 2000-10-07 Indolinones substituees en position 5, leur production et leur utilisation comme medicament

Publications (1)

Publication Number Publication Date
EP1224169A2 true EP1224169A2 (fr) 2002-07-24

Family

ID=7925398

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00966136A Withdrawn EP1224169A2 (fr) 1999-10-13 2000-10-07 Indolinones substituees en position 5, leur production et leur utilisation comme medicament

Country Status (6)

Country Link
EP (1) EP1224169A2 (fr)
AR (1) AR026037A1 (fr)
AU (1) AU7663100A (fr)
CO (1) CO5261507A1 (fr)
DE (1) DE19949209A1 (fr)
WO (1) WO2001027080A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
CN1290844C (zh) 2001-12-27 2006-12-20 施万制药 用作蛋白激酶抑制剂的二氢吲哚酮衍生物
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE102004012070A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
DE102004012068A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue alkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2016049A1 (fr) * 2006-04-24 2009-01-21 Boehringer Ingelheim International GmbH Dérivés de 3- (aminométhylidène) 2-indolinone et leur utilisation en tant qu'inhibiteurs de la prolifération cellulaire
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20230009626A1 (en) * 2018-10-05 2023-01-12 Ichnos Sciences S.A. Indolinone compounds for use as map4k1 inhibitors
CN111285872B (zh) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 吲哚-2-酮衍生物及其制备方法与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476307A (en) * 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0127080A2 *

Also Published As

Publication number Publication date
DE19949209A1 (de) 2001-04-19
AU7663100A (en) 2001-04-23
WO2001027080A2 (fr) 2001-04-19
AR026037A1 (es) 2002-12-26
WO2001027080A3 (fr) 2001-11-22
CO5261507A1 (es) 2003-03-31

Similar Documents

Publication Publication Date Title
EP1071665B1 (fr) Indolinones substituees a effet inhibiteur sur des kinases et des complexes cycline/cdk
EP1224170B9 (fr) Indolinones substituees en position 6, leur preparation et leur utilisation en tant que medicaments
EP1212318B1 (fr) Indolinones substituees utilisees comme inhibiteurs de la tyrosine kinase
EP1115704B1 (fr) Nouvelles indolinones substituees a effet inhibiteur sur differentes kinases et differents complexes cycline/cdk
EP1100779A1 (fr) Indolinones substituees, leur production et leur utilisation comme medicaments
EP1224169A2 (fr) Indolinones substituees en position 5, leur production et leur utilisation comme medicament
DE19924401A1 (de) Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6169106B1 (en) Indolinones having kinase inhibitory activity
EP1379501A1 (fr) Indolinones substituees en position 6 et leur utilisation comme inhibiteurs de kinase
US6545035B1 (en) Substituted indolinones with kinase inhibitory activity
DE19940829A1 (de) Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10042696A1 (de) In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10029285A1 (de) Neue substituierte Indolinone,ihre Herstellung und ihre Verwendung als Arzneimittel
DE19949208A1 (de) In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19937496A1 (de) Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CZ20003788A3 (cs) Substituované indolinony

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020522

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20020522;LV PAYMENT 20020522;MK;RO PAYMENT 20020522;SI PAYMENT 20020522

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG

17Q First examination report despatched

Effective date: 20030227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030910